What are the opening hours?

Monday 9am - 6pm Tuesday 9am - 6pm Wednesday 9am - 6pm Thursday 9am - 6pm Friday 9am - 6pm

MedGenome

Home
India
Bangalore
MedGenome

MedGenome is a leading provider of molecular diagnostics solutions to hospitals and clinicians.

MedGenome is a leading provider of molecular diagnostics solutions to hospitals and clinicians, enabling personalized healthcare. Its innovative offerings in molecular diagnostics apply advanced software and bioinformatics tools to curated omics data, combined with MedGenome’s proprietary knowledge base and powerful analytics. MedGenome’s genomics bioinformatics platform is available to global pharmaceuticals, research and diagnostics organizations. MedGenome has pioneered Whole Genome, Whole Exome and Multi-Gene Panel disease panel based diagnostics in India. MedGenome genomic products and services will empower doctors and patients in matters of health and disease management by providing them with relevant genetic information. MedGenome has developed many single gene tests, disease panels and investigational tests covering Oncology, Pediatrics, Prenatal, Cardiology, Ophthalmology, Neurology, and other specialties. Our OncoMD Cancer Analytics Platform curates and validates genomics and proteomics data captured from leading peer reviewed scientific journals and other relevant data sources. The platform combines curated data with software bioinformatics and powerful analytics to deliver actionable information for clinical diagnosis and treatment decisions. MedGenome also partners with clients on genomic based exploratory research and drug discovery. Our ability to leverage existing longitudinal studies, design population studies from scratch and also conduct follow up studies on cohorts provides valuable benefits to our global research partners

MedGenome was incubated for 2 years as a division of SciGenom Labs, Cochin, India. It was spun off as a separate company with headquarters in Narayana Health City, Bangalore in 2013. MedGenome at Narayana Nethralaya (NN) has a co-located lab spanning over 10,000 sq.ft of lab space at Narayana Nethralaya. MedGenome has a multi faceted team spread across the country, facilitating its pan India operations.

09/01/2026

Featured in Business Today Magazine, Mr. Surajit Chakrabartty, CFO, MedGenome, joins industry experts to share his perspective on how India's healthcare ecosystem is changing, with the growing adoption of genomic diagnostics.

Clinical genomics is now becoming central to the core of decision-making, guiding early disease detection and treatment management for complex diseases. Its demand is rising, producing the fastest adoption phase in India’s short genomics history. Leading this change, MedGenome, India's largest diagnostics company, has served more than a million patients, supported by the latest technologies, AI-driven workflows, and scientific innovation that enhance clinical relevance for the Indian population.

Mr. Chakrabartty says that with growing awareness and rising demand, led by oncology, rare disease diagnostics, and preventive genomics, the future of this sector holds significant untapped potential.

Read the full article: https://www.businesstoday.in/magazine/deep-dive/story/behind-the-goldrush-to-bring-dna-testing-to-india-508859-2025-12-31

07/01/2026

MedGenome’s Lung Cancer Duo (Tumour + Liquid Biopsy) is a dual-layered, end-to-end Next-Generation Sequencing (NGS) approach for advanced lung cancer diagnostics. Parallel tumour tissue and liquid biopsy testing is performed for better characterisation of molecular alterations. It covers actionable genes for SNVs, InDels, CNVs, and fusions critical to lung cancer, delivering faster actionable results that accelerate personalised treatment decisions for clinicians.

To know more about the test,
📞 1800 296 9696 | ✉️ diagnostics@medgenome.com | 🌐medgenome.com

MolecularDiagnostics PersonalisedMedicine ClinicalGenomics MedGenome

02/01/2026

Detecting Minimal Residual Disease (MRD) is critical for improving outcomes and enabling effective patient management in NPM1-mutated AML. MedGenome’s NPM1-MRD Detect, a precision qRT-PCR–based assay, delivers ELN-aligned reports with highly sensitive quantification (

29/12/2025

“I began my career at MedGenome as a genetic counsellor, and today, my role has evolved to encompass genome analysis and clinical reporting. This transition has allowed me to collaborate with multiple stakeholders, which has significantly broadened my experience in the field. The trust and encouragement I've received at MedGenome have been instrumental in my success in this dual role.

I have received consistent support through training, cross-functional collaboration, and opportunities to take on leadership responsibilities, all of which have contributed to my personal and professional growth. I am excited about the future here, knowing there is still so much to learn and contribute.”

― Dhriti Chendil Nathan

24/12/2025

We are delighted to share that Dr. Vedam Ramprasad, PhD, CEO, MedGenome Labs Ltd, has been honoured with the Businessperson of the Year Award (Mid-size Company) 2023–24 at the BioSpectrum Excellence Awards 2025.

We extend our sincere thanks to the distinguished jury, BioSpectrum India, and Dr. Manbeena Chawla, PhD, for this recognition. This is a testament to Dr. Ramprasad's visionary leadership and reflects MedGenome's unwavering commitment to leveraging genetic testing to mitigate the nation’s disease burden, transforming India’s healthcare ecosystem, and positioning India as a global hub for genomics.

22/12/2025

Christmas cheer arrived early at MedGenome! 🎄✨
All our floors came alive with beautifully decorated Christmas trees and twinkling lights, setting the perfect festive mood. The celebrations were made even more special with our Secret Santa tradition, as colleagues exchanged thoughtful gifts, shared laughter, and came together to celebrate the true spirit of the season. Moments like these remind us that beyond science and innovation, it’s the people who make MedGenome truly special.

15/12/2025

Learn how genome-wide methylation profiling is transforming CNS tumour diagnosis, read our blog:
https://diagnostics.medgenome.com/medgenomes-cns-tumour-methylation-classifier-a-breakthrough-in-brain-tumour-diagnostics/

Diagnosing CNS tumors accurately remains one of the biggest challenges in neuro-oncology. MedGenome’s CNS Tumour Methylation Classification Test, India’s first genome-wide methylation-based diagnostic for CNS tumors, helps close the diagnostic gap by delivering a precise molecular fingerprint of the tumor. By refining, confirming, or even redefining the diagnosis, this test empowers clinicians with clarity that guides targeted treatment decisions, improves subtype accuracy, reduces overtreatment, and supports better patient outcomes.

To know more, reach out to us,
📞1800 296 9696 | 📩 diagnostics@medgenome.com

14/12/2025

At MedGenome, the drive to collaborate, innovate, and excel isn't just part of what we do – it's in our genes.

Our annual event, Triple Panga, transformed our office into a lively environment full of creativity, strategic thinking, and bonding. With an enthusiastic turnout, the participants showcased both sharp thinking and perseverance in every game. Through each move, strike, and guess, we strengthened bonds, boosted confidence, and created lasting memories.

12/12/2025

MedGenome was proud to participate in the 10th Annual Conference of the Society for Indian Academy of Medical Genetics (IAMG 2025) in Pune, held from 5th–7th December 2025.

At the event, MedGenome introduced ExomeMAX Reflex Whole Genome Sequencing, presented several scientific posters, and attended an insightful session by Dr. Ramprasad, CEO, MedGenome Labs, on genetic risk stratification in common diseases. We also hosted an engaging genetics quiz, which received enthusiastic participation from attendees.

10/12/2025

In AML, NPM1 mutations influence disease progression and therapeutic strategies.

Even after remission, residual disease cells can persist and lead to relapse. NPM1-MRD Detect assay helps identify early traces of leukemia, and guides timely targeted therapy.

In AML, every cell matters—and every outcome deserves precision. To know more, reach out to us,
📞1800 296 9696 | 📩 diagnostics@medgenome.com

04/12/2025

Explore MedGenome’s world-class genomics lab today!🧪
Visit medgenome.com or call 1800 296 9696 to know more.

Take a peek into MedGenome, South Asia's largest CAP and NABL-accredited multi-omics laboratory. With cutting-edge technologies, AI/ML-enabled tools, and the expertise of our brilliant scientists, we’re pushing the boundaries of healthcare to make genomics accessible for all.

02/12/2025

Featured in for Lung Cancer Awareness Month.

Read here: https://www.timesnownews.com/health/how-genetics-is-changing-everything-we-know-about-lung-cancer-article-153219412

Genetics has now been identified to play a major role in lung cancers, whether triggered by lifestyle and environmental factors or inherited mutations. . Prashanth Bagali explains that understanding the genetic makeup of a tumour is crucial to identifying the exact mutations that influence how the disease develops and how well a patient may respond to treatment. This level of insight is transforming lung cancer care, enabling more precise, targeted therapies and offering patients better outcomes and improved survival rates.

Address

MedGenome Labs Ltd. Sy. Nos. 94/1C And 94/2, Tower 1, Ground Floor, Veerasandra Village, Attibele Hobli, Electronic City Phase-1, Electronics City
Bangalore
560100

Opening Hours

Monday	9am - 6pm
Tuesday	9am - 6pm
Wednesday	9am - 6pm
Thursday	9am - 6pm
Friday	9am - 6pm

Telephone

+9118001033691

Website

http://www.medgenome.com/

Alerts

Be the first to know and let us send you an email when MedGenome posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MedGenome:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Want your practice to be the top-listed Clinic in Bangalore?